Vericiguat Global Study in Participants with Chronic Heart Failure: Design of the VICTOR Trial
European Journal of Heart Failure · 01.02.2025 · 27 (2) · 209-218
DOI: 10.1002/ejhf.3501 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Heart Failure, online erschienen am 30.10.2024. Verfasst von Yogesh N V Reddy und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA. Hauptthemen laut MEDLINE: Heart Failure, Heterocyclic Compounds, 2-Ring, Pyrimidines, Stroke Volume. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NHLBI NIH HHS, Merck Sharp & Dohme LLC., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, Bayer AG, Wuppertal, Germany.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Aims
In the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial, the soluble guanylate cyclase stimulator vericiguat reduced the risk of hospitalization for heart failure (HHF) or cardiovascular death in patients with heart failure (HF) and reduced ejection fraction (HFrEF) with recent worsening HF. The effect of vericiguat in patients with HFrEF without recent worsening HF remains unknown. The VICTOR (Vericiguat Global Study in Participants with Chronic Heart Failure) trial was designed to assess the efficacy and safety of vericiguat in patients with ejection fraction ≤40% without recent worsening HF on a background of current foundational HFrEF therapy.
Methods
The primary endpoint for VICTOR is time to first event for the composite of HHF or cardiovascular death. The trial will also assess the effect of vericiguat on time to cardiovascular death, time to HHF, total HHF, and all-cause death. As an event-driven trial, at least 1080 primary events are expected, but follow-up will continue until the targeted number of at least 590 cardiovascular deaths has been reached. Approximately 6000 participants will be randomized to vericiguat or placebo.
Conclusion
VICTOR is the first large event-driven HFrEF trial performed in the contemporary era of quadruple foundational guideline-directed medical therapy, in a compensated ambulatory HF population. VICTOR will add important information to the evidence of the effects of vericiguat across the spectrum of patients with HFrEF.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA.
- Baylor Scott and White Research Institute, Dallas, TX, USA.
- Department of Medicine, University of Mississippi, Jackson, MS, USA.
- University of North Carolina, Chapel Hill, NC, USA.
- Merck & Co., Inc., Rahway, NJ, USA.
- Colorado Prevention Center Clinical Research, Department of Medicine, University of Colorado, Aurora, CO, USA.
Förderung
- NHLBI NIH HHS
- Merck Sharp & Dohme LLC., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA
- Bayer AG, Wuppertal, Germany
- Merck Sharp & Dohme
- Bayer
Zitieren
APA
Reddy, Y. N. V., Butler, J., Anstrom, K. J., Blaustein, R. O., Bonaca, M. P., Corda, S., Ezekowitz, J. A., Lam, C. S. P., Lewis, E. F., Lindenfeld, J., McMullan, C. J., Mentz, R. J., O'Connor, C., Patel, M., Ponikowski, P., Rosano, G. M. C., Saldarriaga, C. I., Senni, M., Udelson, J., …, & Zannad, F. (2025). Vericiguat Global Study in Participants with Chronic Heart Failure: Design of the VICTOR Trial. European Journal of Heart Failure, 27(2), 209-218. https://doi.org/10.1002/ejhf.3501
Vancouver
Reddy YNV, Butler J, Anstrom KJ, Blaustein RO, Bonaca MP, Corda S, et al. Vericiguat Global Study in Participants with Chronic Heart Failure: Design of the VICTOR Trial. European Journal of Heart Failure. 2025;27(2):209-218. doi:10.1002/ejhf.3501
BibTeX
@article{Reddy2025,
author = {Reddy, Yogesh N V and Butler, Javed and Anstrom, Kevin J and Blaustein, Robert O and Bonaca, Marc P and Corda, Stefano and Ezekowitz, Justin A and Lam, Carolyn S P and Lewis, Eldrin F and Lindenfeld, JoAnn and McMullan, Ciaran J and Mentz, Robert J and O'Connor, Christopher and Patel, Mahesh and Ponikowski, Piotr and Rosano, Giuseppe M C and Saldarriaga, Clara I and Senni, Michele and Udelson, James and Voors, Adriaan A and Zannad, Faiez},
title = {Vericiguat Global Study in Participants with Chronic Heart Failure: Design of the VICTOR Trial},
journal = {European Journal of Heart Failure},
year = {2025},
volume = {27},
number = {2},
pages = {209--218},
doi = {10.1002/ejhf.3501}
}
EUVIMED